Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C2BP
|
|||
| Drug Name |
AG-270
|
|||
| Synonyms |
REOUTEBTFSILJY-UHFFFAOYSA-N; AG 270; 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride; 6-(m-Methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-3(2H)-pyridazinone hydrochloride; Morpholinoethyl-2 methyl-4 (m-methoxyphenyl)-6 pyridazone-3 chlorhydrate [French]; 13299-99-5; AC1L496O; DTXSID20157888; Morpholinoethyl-2 methyl-4 (m-methoxyphenyl)-6 pyridazone-3 chlorhydrate; LS-130006; 6-(3-methoxyphenyl)-4-methyl-2-(2-morpholin-4-ylethyl)pyridazin-3-one hydrochloride
Click to Show/Hide
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | ||
| Company |
Agios Pharmaceuticals Cambridge, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H24ClN3O3
|
|||
| Canonical SMILES |
CC1=CC(=NN(C1=O)CCN2CCOCC2)C3=CC(=CC=C3)OC.Cl
|
|||
| InChI |
1S/C18H23N3O3.ClH/c1-14-12-17(15-4-3-5-16(13-15)23-2)19-21(18(14)22)7-6-20-8-10-24-11-9-20;/h3-5,12-13H,6-11H2,1-2H3;1H
|
|||
| InChIKey |
REOUTEBTFSILJY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 13299-99-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | S-adenosylmethionine synthase type-2 (MAT2A) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Cysteine and methionine metabolism | |||
| Metabolic pathways | ||||
| Biosynthesis of amino acids | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.